Jiménez Cruz Jocelyn M, Vlaar Cornelis P, López-Mejías Vilmalí, Stelzer Torsten
Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States; Department of Pharmaceutical Sciences, University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico 00936, United States.
Department of Pharmaceutical Sciences, University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico 00936, United States.
J Chem Eng Data. 2021 Jan 14;66(1):832-839. doi: 10.1021/acs.jced.0c00908. Epub 2020 Dec 10.
MBQ-167 is a novel, small-molecule dual inhibitor of Rac and Cdc42, small GTPases that are involved in cytoskeletal organization, cell cycle progression, and cell migration. In an mouse model, MBQ-167 has been shown to significantly reduce mammary tumor growth and metastasis and is currently undergoing preclinical studies for the treatment of metastatic cancer. To date, no solubility data have been reported for this compound. For this reason, the present study aims to determine the solubility of this compound in eight neat solvents (acetonitrile, 1-butanol, 2-butanol, ethanol, ethyl acetate, methanol, 1-propanol, and 2-propanol) and two binary solvent mixtures [ethyl acetate (2) + heptane (3) and ethanol (2) + water (3)] between the temperatures of 278.15 and 333.15 K. The results obtained employing the polythermal method show that the solubility of MBQ-167 increases with an increase in temperature in all neat solvents used within this study. Moreover, in the two binary solvent mixtures, the solubility of this compound increases with increasing temperature and decreases with an increasing mass fraction of the antisolvent (heptane or water). The experimental solubility data were correlated using the modified Apelblat and h model equations. The predicted solubility data acquired from the Apelblat and h model equations correlate well with the experimental solubility data as indicated by the low ARD % (≤1.8304 and ≤6.5366, respectively). No solvent-mediated polymorphic phase transitions were observed while performing the solubility studies, and no other solid forms were detected after the recrystallization in the solvents and solvent mixtures. The solubility data determined here can offer pathways to develop pharmaceutical crystallization processes that can further the translation of MBQ-167 into a clinical setting.
MBQ - 167是一种新型小分子双抑制剂,可抑制Rac和Cdc42这两种参与细胞骨架组织、细胞周期进程及细胞迁移的小GTP酶。在小鼠模型中,MBQ - 167已被证明能显著降低乳腺肿瘤的生长和转移,目前正处于转移性癌症治疗的临床前研究阶段。迄今为止,尚未有关于该化合物溶解度的数据报道。因此,本研究旨在测定该化合物在278.15至333.15 K温度范围内,在八种纯溶剂(乙腈、1 - 丁醇、2 - 丁醇、乙醇、乙酸乙酯、甲醇、1 - 丙醇和2 - 丙醇)以及两种二元溶剂混合物[乙酸乙酯(2)+庚烷(3)和乙醇(2)+水(3)]中的溶解度。采用变温法获得的结果表明,在本研究使用的所有纯溶剂中,MBQ - 167的溶解度均随温度升高而增加。此外,在两种二元溶剂混合物中,该化合物的溶解度随温度升高而增加,随抗溶剂(庚烷或水)质量分数的增加而降低。实验溶解度数据使用修正的Apelblat和h模型方程进行关联。从Apelblat和h模型方程获得的预测溶解度数据与实验溶解度数据相关性良好,低ARD%(分别≤1.8304和≤6.5366)表明了这一点。在进行溶解度研究时未观察到溶剂介导的多晶型相变,在溶剂和溶剂混合物中重结晶后也未检测到其他固体形式。此处测定的溶解度数据可为开发药物结晶工艺提供途径,从而推动MBQ - 167向临床应用转化。